iPSC Programs Fail Early on Bad Starting Cell Lines, Pluristyx Warns

Induced pluripotent stem cell programs can derail long before cells reach a production bioreactor, and Pluristyx executives say the root cause is often the starting material itself: many programs begin with cell lines that were never intended for clinical manufacturing.

"It is difficult to find the right cell line," said Benjamin Fryer, PhD, CEO and cofounder of Pluristyx. Researchers frequently build promising processes around readily available lines, then discover the material lacks the provenance, consent, or good manufacturing practice (GMP) pedigree required for human use. By that point, teams may have invested years in process development, animal studies, and publications — only to restart with a new line.

For R&D managers running iPSC portfolios, the message is blunt: choosing starting material is a bioprocessing decision, not merely a research decision.

What changes as scale increases?

When developers move from milliliter-scale work toward liters or tens to hundreds of liters, the process must stay comparable across scales. "The manufacturing process has to be somewhat similar," Fryer said. Passage number and population doublings need controlling so cells at small and large scale are effectively the same biological age.

Production format matters as well. "You need to make sure that the cells are available in the process format you're going to use," Fryer said. A therapy intended for suspension culture should move toward suspension early rather than undergo a disruptive conversion late in development.

Priya Baraniak, PhD, chief commercial and development officer at Pluristyx, put the principle plainly: "Standardizing your input is really important." Even high-quality cells introduce variability if their passage history, characterization, or biological state shifts from run to run.

Why does expansion potential mislead developers?

iPSCs' capacity to expand can create a false sense of security about supply. "We often fall into a false narrative that these cells can be expanded forever and they're an evergreen source," Baraniak said. "They accumulate genetic mutations and aberrations as you expand them." The result can be a process built around cells that no longer behave as intended — a failure mode that surfaces after significant sunk cost.

Beyond raw material, Baraniak said cell manufacturing still relies too heavily on "golden hands": highly skilled operators whose tacit knowledge is hard to reproduce across people, sites, and scales. "You can't rely on just golden hands," she said. Processes must be engineered to minimize operator-dependent decisions and tolerate normal manufacturing variation.

Does automation fix the problem?

Not by itself, according to Fryer. Replacing a human hand with a robotic one does not solve a poorly understood process. Manufacturers first need mechanistic knowledge — why cells respond to particular media, handling steps, environmental conditions, and culture parameters. That understanding can then guide smarter automation, closed systems, and process analytics, rather than locking fragile procedures into hardware.

Clinical readiness also depends on whether donor consents support the intended use, Baraniak said. On top of that, developers face the standard manufacturing demands of robustness, reproducibility, and scale at a cost she described as "clinically and commercially feasible."

Where else could disciplined iPSC manufacturing pay off?

The same manufacturing discipline could expand iPSC use in new approach methodologies (NAMs), including drug screening, toxicology, disease modeling, and engineered tissues. Unlike limited primary tissues, well-controlled iPSC banks can provide renewable human material representing different donors, disease states, and genetically engineered variants. Those models become useful at industrial scale only if they can be manufactured, distributed, and reproduced consistently.

For Baraniak, the reproducibility challenge marks the field's maturity. "We've moved past the point of proving that these therapies have viability, that iPSCs work," she said. "So now it's how do we make them work over and over and over."

That shift — from demonstrating biological possibility to engineering repeatable manufacturing — may define the next phase of iPSC commercialization. Better starting materials, deeper process understanding, automation, and more open sharing of manufacturing experience will not eliminate biological complexity, but they could keep that complexity from becoming the bottleneck that keeps promising iPSC technologies from reaching patients.